Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

Company Overview

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research. The company offers instrument systems as well as consumable reagents and software tools that enable end-to-end proteomic workflows, from sample preparation through data analysis. By focusing on single-molecule detection, Nautilus aims to reveal low-abundance proteins that are often missed by bulk analysis methods.

Nautilus went public in 2021, listing on the Nasdaq under the ticker symbol NAUT, and has since forged collaborations with leading research centers and biotech partners. Its management team brings together experts in biochemistry, engineering and data science, with experience in both academic research and commercial biotechnology. The company continues to expand its R&D capabilities and manufacturing infrastructure to support broader adoption of its proteomics platform.

Looking ahead, Nautilus Biotechnology plans to scale its instrument deployments and refine its analytical software to address emerging challenges in precision medicine and biomarker discovery. By delivering comprehensive proteomic profiles with increased depth and accuracy, the company seeks to empower scientists and clinicians with the tools needed to understand complex diseases and develop novel therapeutics.

Key Stats

• Today's Range: $2.81 to $3.03
• 50-Day Range: $2.29 to $3.95
• 52-Week Range: $0.62 to $4.31
• Volume: 276,938 shs
• Average Volume: 304,701 shs
• Market Capitalization: $363.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Nautilus Biotechnology Stock Analysis - MarketRank™

Nautilus Biotechnology scored higher than 75% of companies evaluated by MarketBeat, and ranked 131st out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Nautilus Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Nautilus Biotechnology has a consensus price target of $4.00, representing about 39.9% upside from its current price of $2.86.

Amount of Analyst Coverage

Nautilus Biotechnology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nautilus Biotechnology is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nautilus Biotechnology is -6.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nautilus Biotechnology has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.86% of the float of Nautilus Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

Nautilus Biotechnology has a short interest ratio ("days to cover") of 2.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nautilus Biotechnology has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nautilus Biotechnology does not currently pay a dividend.

Dividend Growth

Nautilus Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Nautilus Biotechnology has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Nautilus Biotechnology this week, compared to 1 article on an average week.

Search Interest

6 people have searched for NAUT on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Nautilus Biotechnology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $65,250.00 in company stock, which represents 0.0180% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Nautilus Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $65,250.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

41.10% of the stock of Nautilus Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

50.71% of the stock of Nautilus Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NAUT Stock Analysis - Frequently Asked Questions

How have NAUT shares performed this year?

Nautilus Biotechnology's stock was trading at $1.95 on January 1st, 2026. Since then, NAUT shares have increased by 46.7% and is now trading at $2.86.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) released its quarterly earnings results on Tuesday, April, 28th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.03.
Read the conference call transcript.

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's top institutional investors include Citizens Financial Group Inc. RI (0.04%). Insiders that own company stock include Parag Mallick, Sujal M Patel, Anna Mowry, Matthew B Murphy, Kentaro Suzuki and Mary E Godwin.
View institutional ownership trends.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nautilus Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nautilus Biotechnology investors own include JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Home Depot (HD) and Visa (V).

Company Calendar

• Last Earnings: 4/28/2026
• Today: 5/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:NAUT
• CIK: 1808805
• Web: www.nautilus.bio
• Phone: 206-333-2001
• Fax: N/A
• Employees: 130
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Nautilus Biotechnology: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +39.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.04%
• Return on Assets: -29.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.85
• Quick Ratio: 11.85

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.14 per share
• Price / Book: 2.51

Miscellaneous

• Outstanding Shares: 127,079,000
• Free Float: 74,850,000
• Market Cap: $363.45 million
• Optionable: Optionable
• Beta: 0.75